RecruitingEarly Phase 1NCT07145008

Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon


Sponsor

University of Baghdad

Enrollment

20 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection). The main questions it aims to answer are: Does vision improve on the eye chart after the injection? Does the injection lower retinal swelling (reduction in thickness) within 3 months? Participants will: Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT). Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring. Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans. Contact the clinic if they notice pain, redness, new floaters, or worsening vision.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Non-infectious uveitis complicated with macular edema
  • Uveitic macular edema of less than four months' duration
  • Macular edema persisted despite lack of intra-ocular inflammation
  • No response to posterior sub-Tenon triamcinolone acetonide injections

Exclusion Criteria2

  • Those with epiretinal membrane-associated macular edema
  • Below 18 years

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSuprachoroidal triamcinolone acetonide injection

For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.


Locations(1)

Ibn Al-Haitham Eye Teaching Hospital

Baghdad, Iraq

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07145008


Related Trials